Radius Health on-track for record quarterly revenue for TYMLOS-SC

 

• Radius Health (RDUS +4.3%) says that its focus on postmenopausal osteoporotic fracture patients continues to gain traction. In November, a truncated sales month due to the Thanksgiving holiday, Radius added 1,326 net new patients, representing 8% increase from the previous four-month trailing average.
• The current Q4 forecast for TYMLOS-SC net revenue projects a record quarter for the product since its launch. The previous quarterly net revenue high of $56.7M was reported in last year Q4.
• In October, the company entered into a discovery research collaboration with Massachusetts General Hospital to evaluate efficacy, safety, and specificity of small molecules as potential oral anabolic treatment for a broad array of musculoskeletal diseases. The area of focus includes salt inducible kinases and SIK inhibitors.
• https://seekingalpha.com/news/3644604-radius-health-on-track-for-record-quarterly-revenue-for-tymlos-sc